MedTrace Logo

Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana

NCT02281643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-23

No results posted yet for this study

Summary

This study will determine the influence of doxycycline treatment against Wolbachia/M. perstans on immunity against concomitant mycobacterial infections in healthy M. perstans infected individuals. In this regard, the investigators will perform a community-based randomized controlled trial (Phase 2a) in Asante Akim North District. A cohort of 200 participants who are contacts of patients with Tuberculosis or Buruli ulcer, of both sexes with no clinical condition requiring long-term medication but connected with Mansonella perstans will be investigated for the effect of doxycycline on microfilaria, the immune response and development of mycobacterial disease.

Conditions

  • Mansonella Perstans Infection
  • Buruli Ulcer
  • Tuberculosis
  • Co-infection

Interventions

DRUG

Doxycycline

200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm

Sponsors & Collaborators

  • University of Bonn

    collaborator OTHER

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Kwame Nkrumah University of Science and Technology

    lead OTHER

Principal Investigators

  • Richard Phillips O Phillips, MBChB, PhD · Kwame Nkrumah University of Science and Technology

  • Ellis Owusu Dabo, MBChB, PhD · Kumasi Centre for Collaborative Research

  • Alexander Y Debrah, PhD · Kwame Nkrumah University of Science and Technology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
9 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2017-03-15
Completion
2017-03-15

Countries

  • Ghana

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02281643 on ClinicalTrials.gov